Whole Brain Radiation Therapy Does Not Improve the Overall Survival of EGFR-mutant NSCLC Patients with Leptomeningeal Metastasis

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2019 Sep 16

PMID 31521171

Citations 16

Authors

Weiwei Yan

Yang Liu

Ji Li

Anqin Han

Li Kong

Jinming Yu

Hui Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor receptor (EGFR) mutations. The role of whole brain radiation therapy (WBRT) in the treatment of EGFR-mutant NSCLC patients with LM is not conclusive. Therefore, we conducted a retrospective study to evaluate the therapeutic effect of WBRT in this setting.

Methods: EGFR-mutant NSCLC patients with LM, who had previously received treatment at the Shandong Cancer Hospital and Institute from July 2014 to March 2018 were reviewed retrospectively. LM was diagnosed by positive CSF cytology and/or leptomeningeal-enhanced magnetic resonance imaging (MRI). Survival was estimated using the Kaplan-Meier method.

Results: In total, 51 EGFR-mutated NSCLC patients with LM were eligible for analysis, subdivided into 26 in the WBRT group and 25 in the non-WBRT group. No significant differences were observed in intracranial ORR (15.4% vs. 16%, p = 0.952) and DCR (34.7% vs. 28%, p = 0.611) between the two groups. The median iPFS and OS for the entire cohort were 3.3 months (95% CI: 2.77-3.83) and 12.6 months (95% CI: 9.66-15.54), respectively. No difference in iPFS was observed between the WBRT and non-WBRT groups (median 3.9 vs. 2.8 months; HR = 0.506, p = 0.052). The median OS was 13.6 months in the WBRT group, compared with 5.7 months in the non-WBRT group (HR = 0.454, p = 0.022). Multivariate analyses of OS showed that KPS ≥ 80 at the time of LM diagnosis (HR = 0.428, 95% CI: 0.19-0.94; p = 0.034) and the administration of EGFR-TKIs (HR = 0.258, 95% CI: 0.11-0.58; p = 0.001) were independent predictors of survival, but WBRT (HR = 0.49, 95% CI: 0.24-1.01; p = 0.54) was not. Toxicities associated with WBRT or other treatment were rare.

Conclusion: For EGFR-mutated NSCLC patients with LM, WBRT did not improve intracranial treatment response and survival statistically.

Citing Articles

The research progress on meningeal metastasis in solid tumors.

Yue Y, Ren Y, Lu C, Jiang N, Wang S, Fu J Discov Oncol. 2025; 16(1):254.

PMID: 40019647 PMC: 11871263. DOI: 10.1007/s12672-025-01950-4.

Case report: A case report and literature review on the efficacy of high-dose aumolertinib combined intrathecal pemetrexed by Ommaya reservoir for EGFR-mutated NSCLC with leptomeningeal metastasis as the initial symptoms.

Zhong M, Zhou L, Guo J, Chen C, Wang W, Huang X Front Oncol. 2025; 15:1502934.

PMID: 39949743 PMC: 11821504. DOI: 10.3389/fonc.2025.1502934.

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations.

Ji X, Jiang R, Liu T, Provencio M, Lee S, Zhan Q Transl Lung Cancer Res. 2024; 13(7):1695-1707.

PMID: 39118876 PMC: 11304138. DOI: 10.21037/tlcr-24-477.

Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.

Rogawski D, Cao T, Ma Q, Roy-OReilly M, Yao L, Xu N J Neurooncol. 2024; 170(1):209-217.

PMID: 39073687 DOI: 10.1007/s11060-024-04788-y.

Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.

Barbour A, Kotecha R, Lazarev S, Palmer J, Robinson T, Yerramilli D Adv Radiat Oncol. 2024; 9(2):101377.

PMID: 38405313 PMC: 10885590. DOI: 10.1016/j.adro.2023.101377.

References

Chamberlain M . Neoplastic meningitis. Oncologist. 2008; 13(9):967-77. DOI: 10.1634/theoncologist.2008-0138. View

Yi H, Kim H, Kim Y, Han S, Oh D, Lee S . Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2008; 65(1):80-4. DOI: 10.1016/j.lungcan.2008.10.016. View

So T, Inoue M, Chikaishi Y, Nose N, Sugio K, Yasumoto K . Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today. 2009; 39(7):598-602. DOI: 10.1007/s00595-008-3909-1. View

Chamberlain M . Leptomeningeal metastasis. Curr Opin Oncol. 2010; 22(6):627-35. DOI: 10.1097/CCO.0b013e32833de986. View

Morris P, Reiner A, Szenberg O, Clarke J, Panageas K, Perez H . Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2011; 7(2):382-5. DOI: 10.1097/JTO.0b013e3182398e4f. View

Park J, Kim Y, Lee J, Lee K, Kim J, Bang S . Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2011; 76(3):387-92. DOI: 10.1016/j.lungcan.2011.11.022. View

Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K . Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012; 77(1):134-9. DOI: 10.1016/j.lungcan.2012.03.002. View

Zeng Y, Zhang L, Liao H, Liang Y, Xu F, Liu J . Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev. 2012; 13(3):909-14. DOI: 10.7314/apjcp.2012.13.3.909. View

Chamberlain M, Eaton K . Is there a role for whole brain radiotherapy in the treatment of leptomeningeal metastases?. J Thorac Oncol. 2012; 7(7):1204. DOI: 10.1097/JTO.0b013e3182572ecf. View

10.

Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y . Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012; 70(3):399-405. DOI: 10.1007/s00280-012-1929-4. View

11.

Lee S, Lee J, Nam D, Ahn Y, Han J, Sun J . Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013; 8(2):185-91. DOI: 10.1097/JTO.0b013e3182773f21. View

12.

Gwak H, Joo J, Kim S, Yoo H, Shin S, Han J . Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol. 2013; 8(5):599-605. DOI: 10.1097/JTO.0b013e318287c943. View

13.

Lee E, Keam B, Kim D, Kim T, Lee S, Chung D . Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013; 8(8):1069-74. DOI: 10.1097/JTO.0b013e318294c8e8. View

14.

Lee Y, Han J, Kim H, Yun T, Lee G, Kim H . Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol. 2013; 115(1):95-101. DOI: 10.1007/s11060-013-1199-y. View

15.

Riess J, Nagpal S, Iv M, Zeineh M, Gubens M, Ramchandran K . Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014; 15(3):202-6. PMC: 6314305. DOI: 10.1016/j.cllc.2013.12.009. View

16.

Kuiper J, Hendriks L, van der Wekken A, de Langen A, Bahce I, Thunnissen E . Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer. 2015; 89(3):255-61. DOI: 10.1016/j.lungcan.2015.05.023. View

17.

Gong L, Xiong M, Huang Z, Miao L, Fan Y . Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Lung Cancer. 2015; 89(3):268-73. DOI: 10.1016/j.lungcan.2015.06.001. View

18.

Liao B, Lee J, Lin C, Chen Y, Chang C, Ho C . Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015; 10(12):1754-61. DOI: 10.1097/JTO.0000000000000669. View

19.

Hyun J, Jeong I, Joung A, Cho H, Kim S, Kim H . Leptomeningeal metastasis: Clinical experience of 519 cases. Eur J Cancer. 2016; 56:107-114. DOI: 10.1016/j.ejca.2015.12.021. View

20.

Tan C, Cho B, Soo R . Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016; 93:59-68. DOI: 10.1016/j.lungcan.2016.01.003. View